ReBA Therapeutics Inc
The respiratory bridge adaptor improves the efficiency and precision of delivering aerosolized medications for patients while on a mechanical ventilator.
ReBA Therapeutics is dedicated to advancing the Temple University patent for the "respiratory bridge adaptor" (RBA) from the concept through to pre-commercialization. Our Development Plan will require $650,000 over 18 months and the US Market potential is approximately $60 M (50% of the global market). Industry "comps" indicate a valuation of $20 M upon completion of product development, yielding an ROI of 14X.